Trelegy Archives -

European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension

GSK hits trouble with Trelegy as EU regulators block asthma indication

https://pharmaphorum.com/news/gsk-hits-trouble-with-trelegy-as-eu-regulators-block-asthma-indication/

GlaxoSmithKline saw a recovery in its vaccine sales in the third quarter after a big hit in the

Vaccine sales recover at GSK in Q3, but lockdown fears weigh on shares

https://pharmaphorum.com/news/vaccine-sales-recover-at-gsk-in-q3-but-lockdown-fears-weigh-on-shares/

Novartis has moved a step closer to EU approval of its three-drug asthma therapy Enerzair Breezhaler, and now

Novartis on point in EU for asthma triple as CHMP backs Enerzair

https://pharmaphorum.com/news/novartis-on-point-in-eu-for-asthma-triple-as-chmp-backs-enerzair/

GlaxoSmithKline is expecting flat earnings this year, having earlier forecast a decline, as rising sales of new drugs

Shingrix and Trelegy shield GSK from Advair fallout

https://pharmaphorum.com/news/gsk-advair-shingles-vaccine-trelegy/

GlaxoSmithKline CEO Emma Walmsley has been predicting big things for respiratory triple therapy Trelegy in the next couple

Trial could unlock asthma use for GSK’s Trelegy

https://pharmaphorum.com/news/trial-could-unlock-asthma-use-for-gsks-trelegy/

Trelegy